Navigation Links
NKT Therapeutics Presents Data on Potential Antibody Treatment for Sickle Cell Disease
Date:12/6/2012

WALTHAM, Mass., Dec. 6, 2012 /PRNewswire/ -- NKT Therapeutics, Inc., a privately held biotechnology company, announced preclinical study results supporting the potential of its lead therapeutic candidate, NKTT120, as an innovative approach to the treatment of sickle cell disease. Preclinical studies of NKTT120, a humanized monoclonal antibody, showed its ability to generate a safe, rapid, specific and complete depletion of invariant Natural Killer T cells (iNKT cells) 24 hours post dosing, thus  offering a means to reduce the chronic inflammation associated with sickle cell disease pathology. NKT Therapeutics plans to initiate a clinical trial of NKTT120 in patients with stable sickle cell disease in the first quarter of 2013.

(Logo: http://photos.prnewswire.com/prnh/20121203/MM23274LOGO)

The study will be presented on December 9 at the American Society of Hematology meeting in Atlanta as a poster presentation entitled, "The Safety Evaluation of NKTT120, an iNKT Cell Depleting Antibody in the Cynomolgus Monkey." An abstract of the study has been published online at https://ash.confex.com/ash/2012/webprogram/Paper50259.html

NKTT120 is a humanized monoclonal antibody that results in a safe, rapid, specific and complete depletion of iNKT cells. The presented research showed that a specific and complete depletion of iNKT cells was observed at the earliest post dosing measurement at 24 hours, and was maintained throughout the 85 day study. Investigators observed no adverse events, infections, or cytokine release.  T cell-dependent antibody response to KLH antigen was not affected by NKTT120 treatment. 

Chronic inflammation is associated with the pathology of sickle cell disease, and studies by NKT Therapeutics and others have found an increased ratio of activated iNKT cells in the
'/>"/>

SOURCE NKT Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Cell Therapeutics Reports on Cooperative Group Sponsored Trial of Brostallicin in Patients with Metastatic Triple-Negative Breast Cancer
2. Smith & Nephew Announces Agreement To Acquire Assets Of Healthpoint Biotherapeutics
3. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
4. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
5. Cell Therapeutics, Inc. (CTI) to Present at Jefferies 2012 Global Healthcare Conference
6. Novel Cancer Immune Therapy Developer Oncos Therapeutics Appoints Experienced Industry Leader Frans Wuite as President and CEO
7. United Therapeutics Corporation To Announce Third Quarter 2012 Financial Results Before Market Open On Thursday, November 1, 2012
8. Northwest Biotherapeutics Appoints Pharma Industry Veteran As CEO Of German Subsidiary
9. Alzheimers Therapeutics Reviewed by NeuroPerspective
10. Parthenon Identifies Emerging Opportunities in Targeted Payload Cancer Therapeutics
11. Global Acute Myeloid Leukemia (AML) Therapeutics Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... PA (PRWEB) June 18, 2013 Demanding ... Ball Lenses engineered of synthetic Sapphire and Glass Ball ... sizes from Swiss Jewel Company , of Philadelphia ... by expanding and collimating the light beams without the ... optical clarity and natural durability (9 mohs) make it ...
(Date:6/18/2013)... DuPont welcomes 48 of the nation’s finest ... AgriScience Teachers Ambassador Academy this week (NATAA) at the ... , The NATAA “Ag Academy” is a professional ... project of the National FFA Foundation and ... The highly recommended agriscience teachers, who are participating ...
(Date:6/18/2013)... , June 18, 2013 ... using the company,s  proprietary AMCA Guided Bone Regeneration (GBR) Dental ... implants. A common problem encountered when patients have ... of sufficient bone volume to house the implant. Consequently there ... bone substitute until the natural bone regenerates. The bone substitute ...
(Date:6/18/2013)... 18, 2013  regulated information — Global biopharmaceutical company ... today announced the launch of a new Pledge campaign ... The Pledge empowers the millions of ... make a personal commitment to demand more: greater understanding ... team and additional partial-onset seizure control.  More information is ...
Breaking Biology Technology:Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2DuPont Sponsors National AgriScience Ambassador Academy 2DuPont Sponsors National AgriScience Ambassador Academy 3RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 2Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 3Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 4Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 5Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 6
... , , BOTHELL, Wash., ... BLFS), a leading developer, manufacturer, and marketer of biopreservation ... Sigma-Aldrich(R) will distribute the Company,s proprietary HypoThermosol and CryoStor ... distribution agreement. , , (Logo: ...
... , , , ... Sept. 14 Tobira Therapeutics Inc., a clinical stage ... the treatment of life-threatening and life-altering infectious diseases, today ... multiple-dose randomized study of TBR-652 in sixty healthy volunteers. ...
... ATLANTA, Sept. 14 CryoLife, Inc. (NYSE: ... and cardiovascular tissue processing company, announced today that it is scheduled ... the Grand Hyatt New York in New York City. , ... of CryoLife, Inc., will present Monday, September 21 at 2:00 p.m., ...
Cached Biology Technology:BioLife Solutions Announces HypoThermosol(R) and CryoStor(TM) Distribution Agreement With Sigma-Aldrich 2BioLife Solutions Announces HypoThermosol(R) and CryoStor(TM) Distribution Agreement With Sigma-Aldrich 3Tobira Therapeutics Inc. Announces Phase I Pharmacokinetic Data of TBR-652 for the Treatment of HIV 2CryoLife to Present at UBS Global Life Sciences Conference 2
(Date:6/17/2013)... virus in patients with severe brain infections in Vietnam. ... is responsible for the symptoms of disease. , The ... of 644 patients with severe brain infections in the ... of the 122 patients with non-infectious brain disorders that ... nervous system are often fatal and patients who do ...
(Date:6/17/2013)... ST. LOUIS -- In research published in Biochemical ... describe a technology that can detect new, previously unknown ... for viruses even when doctors have not identified a ... , In the new approach, scientists use ... discover viruses. , Taking advantage of the complete deciphering ...
(Date:6/17/2013)... a sugar alcohol produced by fungi, bacteria, and algae, ... The sweetener is also used in the medical field ... to flush out excess fluids and used during surgery ... ease the passage of other drugs. , Now Profs. ... Department of Molecular Microbiology and Biotechnology and the Sagol ...
Breaking Biology News(10 mins):New virus isolated from patients with severe brain infections 2New virus isolated from patients with severe brain infections 3Saint Louis University researchers discover a way to detect new viruses 2Saint Louis University researchers discover a way to detect new viruses 3Artificial sweetener a potential treatment for Parkinson's disease 2
... , Dr. Don Walsh, who co-piloted the historic 1960 deep-sea voyage ... Navy in a ceremony on at 10 a.m. April 15 at ... the only living human to have visited the Challenger Deep ... Walsh is best-known for navigating the bathyscaphe (deep submergence vehicle) Trieste ...
... at The Scripps Research Institute have synthesized a new nano-scale scientific ... off as it detects metallic ions in its immediate surroundings. ... of the International Edition of the journal Angewandte Chemie, this molecule ... in the test tube, and it has potential to be developed ...
... with medical formulations to be accepted by the U.S. Food ... that has serious ethical and moral implications. New research in ... Tel Aviv University,s Faculty of Engineering holds a promise that ... experimental trials. Dr. Gefen,s research into fat cells, published ...
Cached Biology News:New nano-tool synthesized at Scripps Research Institute 2A lab rat -- created in the lab 2
Immunogen: Synthetic peptide: N(171) H G F L S A D Q QL I K(183) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Chicken polyclonal to Uridine Phosphorylase 1 ( ... Antigen: Synthetic peptide: MAATGANAEK ... PGRDYPNICA GTDRYAMYK, corresponding to amino acids 1-99 ... Entrez Gene ID: 7378 ...
Request Info...
Lingo-1 (K-13)...
Biology Products: